Cargando…

Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy

PURPOSE: Hematotoxicity is a potentially dose-limiting adverse event in patients with metastasized castration-resistant prostate cancer (mCRPC) undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT). We aimed to identify clinical or PSMA-targeted imaging-derived para...

Descripción completa

Detalles Bibliográficos
Autores principales:	Widjaja, Liam, Werner, Rudolf A., Ross, Tobias L., Bengel, Frank M., Derlin, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484194/ https://www.ncbi.nlm.nih.gov/pubmed/34041564 http://dx.doi.org/10.1007/s00259-021-05412-1

Ejemplares similares

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2022)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment
por: Derlin, Thorsten, et al.
Publicado: (2021)

Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Derlin, Thorsten, et al.
Publicado: (2021)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
por: Werner, Rudolf A., et al.
Publicado: (2019)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Personalized prediction of mode of cardiac death in heart failure using supervised machine learning in the context of cardiac innervation imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
por: Jones, Wallace, et al.
Publicado: (2020)

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
por: Henkenberens, Christoph, et al.
Publicado: (2020)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
por: Lundmark, Fanny, et al.
Publicado: (2022)

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
por: Ohlendorf, Fiona, et al.
Publicado: (2021)

(18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

Hematotoxicity and carcinogenicity of benzene.
por: Aksoy, M
Publicado: (1989)

Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suv(max)) In Laryngeal and Hypopharyngeal Cancer
por: Werner, Jonas, et al.
Publicado: (2019)

Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with (177)Lu-PSMA I&T therapy
por: Xue, Song, et al.
Publicado: (2022)

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Seifert, Robert, et al.
Publicado: (2020)

(177)Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
por: Sadaghiani, Mohammad S., et al.
Publicado: (2022)

Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with (177)Lu-PSMA
por: Moazemi, Sobhan, et al.
Publicado: (2021)

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy
por: Rosar, Florian, et al.
Publicado: (2021)

Hematotoxicity and carcinogenicity of inhaled benzene.
por: Cronkite, E P, et al.
Publicado: (1989)

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
por: Cytawa, Wojciech, et al.
Publicado: (2023)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
por: Deberle, Luisa M., et al.
Publicado: (2020)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand (212)Pb-NG001
por: Stenberg, Vilde Yuli, et al.
Publicado: (2022)

PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?
por: Rizzo, Alessio, et al.
Publicado: (2022)

Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
por: Jang, Albert, et al.
Publicado: (2023)

Renal Safety of [(177)Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
por: Rosar, Florian, et al.
Publicado: (2021)

Joint EANM/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)
por: Kratochwil, Clemens, et al.
Publicado: (2023)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Streamlined Schemes for Dosimetry of (177)Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
por: Kurth, Jens, et al.
Publicado: (2021)

Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
por: Tschan, Viviane J., et al.
Publicado: (2021)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
por: Hoshi, Seiji, et al.
Publicado: (2023)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction
por: Werner, Rudolf A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fkq46iskc9jdq2p3p25q2d61va